I am a male endurance cyclist on testosterone replacement therapy for >15 years with a negative preliminary genetic test for hypertrophic cardiomyopathy (extent of testing unknown); what cardiac imaging or further testing should I undergo to rule out HCM?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cardiac Imaging Recommendation for HCM Screening

You need a comprehensive cardiac MRI (CMR) with late gadolinium enhancement (LGE) as your primary imaging modality, supplemented by stress echocardiography to assess for exercise-induced left ventricular outflow tract obstruction (LVOTO), given your endurance cycling activity and negative preliminary genetic testing 1, 2.

Why Cardiac MRI is Essential

Your negative genetic test does not rule out HCM. The 2024 AHA/ACC guidelines emphasize that genetic testing in HCM probands should focus on strong evidence genes (MYH7, MYBPC3, TNNI3, TNNT2, TPM1, MYL2, MYL3, ACTC1), but approximately 30-40% of HCM patients have no identifiable pathogenic variant even with comprehensive testing 1. The extent of your genetic testing is unknown, which is a critical gap.

Cardiac MRI is superior to echocardiography alone because it:

  • Detects segmental hypertrophy in areas poorly visualized by echo (anterolateral free wall, apex) 3
  • Identifies myocardial fibrosis through LGE, which has prognostic significance 2, 4
  • Provides precise measurement of wall thickness and cardiac mass 5
  • Can detect subtle phenotypic features in the "gray zone" between athlete's heart and early HCM 2

Additional Testing Algorithm

1. Stress Echocardiography with CPET (Cardiopulmonary Exercise Testing)

  • Critical for endurance athletes because LVOTO may only manifest during exercise 6, 7
  • Measures peak VO2, which predicts clinical outcomes and heart failure progression 7
  • Assesses exercise-induced diastolic dysfunction and pulmonary pressures 7
  • Your case report parallel showed an athlete with normal resting imaging but severe LVOTO (150 mmHg gradient) only on stress testing 6

2. Extended Holter Monitoring (48-72 hours)

  • Screen for ventricular arrhythmias during training
  • Assess for chronotropic incompetence, which associates with adverse outcomes 7

3. Repeat/Expanded Genetic Testing

  • If your initial test was a limited panel, pursue comprehensive sarcomere gene sequencing 1
  • Consider testing for HCM phenocopies (storage diseases, mitochondrial disorders) given your prolonged testosterone use, which can cause cardiac hypertrophy 1

Critical Testosterone Consideration

Your 15+ years of testosterone replacement therapy complicates the picture. While the FDA label 8 doesn't specifically list cardiac hypertrophy as a primary concern, exogenous androgens can cause left ventricular hypertrophy independent of HCM. This makes distinguishing pathological from physiological (athlete's heart + testosterone effect) hypertrophy even more challenging. CMR with tissue characterization (native T1 mapping, T2 values) can help differentiate these entities 2.

Common Pitfalls to Avoid

  • Don't rely solely on echocardiography - it misses 15-20% of HCM cases, particularly apical variants 3, 9
  • Don't assume negative genetics = no HCM - the guidelines explicitly state that cascade genetic testing is not useful when no pathogenic variant is found, but this doesn't exclude the diagnosis in you as the potential proband 1
  • Don't skip stress testing - resting studies miss exercise-induced obstruction in symptomatic athletes 6
  • Don't ignore the testosterone variable - discuss with your cardiologist whether temporary cessation might clarify the diagnosis

Ongoing Surveillance

If initial comprehensive workup is negative, the 2015 Bethesda guidelines suggest that genotype-positive/phenotype-negative individuals can participate in competitive athletics 3. However, you need serial imaging every 12-24 months through age 20-25 (if younger) or every 3-5 years if older, as phenotypic conversion can occur at any age 3, 10.

The combination of CMR with LGE, stress echo with CPET, and comprehensive genetic retesting provides the most robust assessment for ruling out HCM in your high-risk scenario as an endurance athlete on long-term testosterone therapy.

References

Research

Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.

Journal of the American College of Cardiology, 2022

Research

Hypertrophic Cardiomyopathy.

Current heart failure reports, 2024

Related Questions

What are the indications, dosing regimen, contraindications, and common adverse effects of Camzyos (mavacamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults?
What exercise regimen is recommended for a patient with symptomatic obstructive hypertrophic cardiomyopathy?
What precautions should a young athlete with hypertrophic obstructive cardiomyopathy follow?
How can I explain hypertrophic cardiomyopathy (HCM) to a patient?
How should I manage a patient with hypertrophic cardiomyopathy who has experienced a rapid increase in late gadolinium enhancement from 4% to 12% over one year, new systolic anterior motion (SAM) of the mitral valve, new right‑ventricular wall thickening, and a newly detected supraventricular tachyarrhythmia on Holter monitoring?
In a mechanically ventilated patient with uncertain chronic obstructive pulmonary disease or asthma who develops fever and purulent tracheal secretions after a few days, what is the most effective single intervention to prevent ventilator-associated infection?
What is the appropriate ceftriaxone (ceftriaxone) injection dose and duration for a male urinary tract infection?
In a patient diagnosed with ocular myasthenia gravis, are systemic symptoms of myasthenia gravis also expected?
What is the appropriate management for a 25-year-old female with low serum vitamin B12?
Which of the following are appropriate components of therapeutic management for systemic vasculitis with renal involvement: maintenance therapy with angiotensin-converting enzyme (ACE) inhibitors, induction therapy with high-dose corticosteroids alone, administration of cyclophosphamide or rituximab during the acute phase, administration of azathioprine during the acute phase, or induction therapy with corticosteroids and immunosuppressants?
How should I manage a patient with a 2‑year history of intense nasal pruritus, constant bright‑white rhinorrhea with occasional small hard black particles, increased salivation, onset after pneumonia hospitalization, and comorbid diabetes and hypertension treated with metformin, aspirin, and losartan?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.